Title : A dietary supplement containing lactobacillus delbrueckii subsp. bulgaricus improves clinical manifestations of functional dyspepsia and patient's quality of life, which is maintained one year after the end of treatment
Abstract:
Background: Functional Dyspepsia (FD) is a common disorder that is difficult to treat and has a significant negative impact on the quality of life of patients. There is growing evidence that the small intestinal microbiota plays a role in the pathophysiology of FD.
Aim: To study the effect of a product containing a lyophilizate of Lactobacillus delbrueckii subsp. bulgaricus strain 9702 (IMV B-7085) and its metabolic products on the clinical manifestations of the disease and the quality of life of patients with functional dyspepsia.
Materials and Methods: 37 patients with functional dyspepsia, with an average age of 45.9±2.5 years (16 men and 21 women), were included in the study. We analyze the results of the GSRS questionnaire before treatment, after completing a fifteen-day course of taking the probiotic additive, which contained Lactobacillus delbrueckii subsp. bulgaricus, and 15 days after the end of the course. In addition, we evaluate the dynamics of quality of life based on the analysis of the MOS-SF-36 questionnaires, completed by patients before treatment and on the 30th day of observation. Furthermore, we conducted a similar assessment of the GSRS questionnaire results and the quality-of-life evaluation one year after treatment with Lactobacillus delbrueckii subsp. bulgaricus (long-term outcomes).
Results: Comparing the total score of the GSRS questionnaire on the 15th day of taking the probiotic drug and 15 days after the end of the 15-day course of taking the drug, found a significant (24.31±1.67 points and 21.29±1.27 points respectively, p<0.05) decrease in the total score, compared to the value before treatment (39.64±2.34 points). Analysis of the quality of life, according to the SF-36 questionnaire, showed a significant increase (p<0.05) in the clusters of physical functioning (PF ? 91.25±2.84 vs 81.82±3.22), role functioning (RF ? 82.29±6.47 vs 62.50±7.44), pain intensity (BP ? 84.58±3.71 vs 57.86±4.59) and general health (GH ? 64.58±4.18 vs 51.07±3.37) on the 30th day of observation. Comparison of the psychological component of health revealed a significant increase (p<0.05) in the quality of life in the social functioning cluster (SF ? 85.94±4.14 vs 72.77±3.97) on the 30th day of observation. In other psychological health clusters, a tendency to increase indicators was established, but it was not statistically significant (p>0.05). Evaluation of long-term results (one year after treatment) revealed long-term improvement in gastrointestinal symptoms, as indicated by the GSRS (total score: 28.73±3.13 points versus 39.64±2.34 points before treatment). Analysis of quality of life one year after treatment revealed a significant increase (p<0.05) compared to the results before treatment in the pain intensity cluster (AT ? 73.21±5.23 vs. 57.86±4.59), general health (GH ? 60.87±4.36 vs. 51.07±3.37), and social functioning cluster (SF ? 83.75±4.05 vs. 72.77±3.97).
Conclusions: Taking a dietary supplement containing the strain Lactobacillus delbrueckii subsp. bulgaricus 9702 (IMV B-7085) improves the clinical manifestations of functional dyspepsia, as evidenced by a reduction in the severity of gastrointestinal symptoms and an improvement in the quality of life of these patients, immediately after treatment and maintained one year after it.
Keywords: Lactobacillus Delbrueckii Subsp. Bulgaricus, Functional Dyspepsia, GSRS Questionnaire, Quality of Life, Nutritional Support, Long-Term Clinical Outcomes.
